192 related articles for article (PubMed ID: 35774156)
1. Parallel imaging of coagulation pathway proteases activated protein C, thrombin, and factor Xa in human plasma.
Modrzycka S; Kołt S; Polderdijk SGI; Adams TE; Potoczek S; Huntington JA; Kasperkiewicz P; Drąg M
Chem Sci; 2022 Jun; 13(23):6813-6829. PubMed ID: 35774156
[TBL] [Abstract][Full Text] [Related]
2. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
[TBL] [Abstract][Full Text] [Related]
3. Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.
Posma JJ; Grover SP; Hisada Y; Owens AP; Antoniak S; Spronk HM; Mackman N
Arterioscler Thromb Vasc Biol; 2019 Jan; 39(1):13-24. PubMed ID: 30580574
[TBL] [Abstract][Full Text] [Related]
4. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.
McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC
Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
6. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates.
Cho K; Tanaka T; Cook RR; Kisiel W; Fujikawa K; Kurachi K; Powers JC
Biochemistry; 1984 Feb; 23(4):644-50. PubMed ID: 6370301
[TBL] [Abstract][Full Text] [Related]
7. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
8. Approaches to selective peptidic inhibitors of factor Xa.
Bromfield KM; Quinsey NS; Duggan PJ; Pike RN
Chem Biol Drug Des; 2006 Jul; 68(1):11-9. PubMed ID: 16923021
[TBL] [Abstract][Full Text] [Related]
9. Role of residue 99 at the S2 subsite of factor Xa and activated protein C in enzyme specificity.
Rezaie AR
J Biol Chem; 1996 Sep; 271(39):23807-14. PubMed ID: 8798609
[TBL] [Abstract][Full Text] [Related]
10. Aminonaphthalenesulfonamides, a new class of modifiable fluorescent detecting groups and their use in substrates for serine protease enzymes.
Butenas S; Orfeo T; Lawson JH; Mann KG
Biochemistry; 1992 Jun; 31(23):5399-411. PubMed ID: 1606166
[TBL] [Abstract][Full Text] [Related]
11. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
Chu V; Brown K; Colussi D; Gao J; Bostwick J; Kasiewski C; Bentley R; Morgan S; Guertin K; Pauls HW; Gong Y; Zulli A; Perrone MH; Dunwiddie CT; Leadley RJ
Thromb Res; 2001 Aug; 103(4):309-24. PubMed ID: 11562341
[TBL] [Abstract][Full Text] [Related]
13. Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samples.
Poreba M; Groborz K; Vizovisek M; Maruggi M; Turk D; Turk B; Powis G; Drag M; Salvesen GS
Chem Sci; 2019 Sep; 10(36):8461-8477. PubMed ID: 31803426
[TBL] [Abstract][Full Text] [Related]
14. Protein Z-dependent protease inhibitor (ZPI) is a physiologically significant inhibitor of prothrombinase function.
Huang X; Swanson R; Kroh HK; Bock PE
J Biol Chem; 2019 May; 294(19):7644-7657. PubMed ID: 30918026
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of a novel factor Xa inhibitor, RPR 130737.
Chu V; Brown K; Colussi D; Choi YM; Green D; Pauls HW; Spada AP; Perrone MH; Leadley RJ; Dunwiddie CT
Thromb Res; 2000 Jul; 99(1):71-82. PubMed ID: 11012377
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.
Nar H; Bauer M; Schmid A; Stassen JM; Wienen W; Priepke HW; Kauffmann IK; Ries UJ; Hauel NH
Structure; 2001 Jan; 9(1):29-37. PubMed ID: 11342132
[TBL] [Abstract][Full Text] [Related]
17. Ultrasensitive fluorogenic substrates for serine proteases.
Butenas S; DiLorenzo ME; Mann KG
Thromb Haemost; 1997 Oct; 78(4):1193-201. PubMed ID: 9364984
[TBL] [Abstract][Full Text] [Related]
18. Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.
Gadi I; Fatima S; Elwakiel A; Nazir S; Mohanad Al-Dabet M; Rana R; Bock F; Manoharan J; Gupta D; Biemann R; Nieswandt B; Braun-Dullaeus R; Besler C; Scholz M; Geffers R; Griffin JH; Esmon CT; Kohli S; Isermann B; Shahzad K
Circ Res; 2021 Feb; 128(4):513-529. PubMed ID: 33353373
[TBL] [Abstract][Full Text] [Related]
19. Factor Xa in mouse fibroblasts may induce fibrosis more than thrombin.
Kitasato L; Yamaoka-Tojo M; Hashikata T; Ishii S; Kameda R; Shimohama T; Tojo T; Ako J
Int Heart J; 2014; 55(4):357-61. PubMed ID: 24942638
[TBL] [Abstract][Full Text] [Related]
20. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
Papadaki S; Tselepis AD
Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
